drugset / Trial / NCT04457856

A Study of TJ003234 in Rheumatoid Arthritis Patients

NCT04457856

Phase 1 Unknown 63 enrolled I-Mab Biopharma US Limited
RandomizedParallel-groupSingle-blindTreatment

Summary

Study Purpose and Design: A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose and Multiple Ascending Doses of TJ003234 in Rheumatoid Arthritis Patients.

Timeline

Start
2020-08-06
Primary completion
2023-03
Completion
2023-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Plonmarlimab Monoclonal antibody 0.3 mg/kg Intravenous
Subject Plonmarlimab Monoclonal antibody 1 mg/kg Intravenous
Subject Plonmarlimab Monoclonal antibody 3 mg/kg Intravenous
Subject Plonmarlimab Monoclonal antibody 6 mg/kg Intravenous
Subject Plonmarlimab Monoclonal antibody 10 mg/kg Intravenous

Indications